Behind Sanofi’s Diabetes and Cardiovascular Portfolio in 3Q17



Diabetes and cardiovascular franchise

Sanofi’s (SNY) diabetes and cardiovascular portfolio includes Lantus, Toujeo, Multaq, and Praluent. These drugs reported revenues of 1.67 billion euros for 3Q17, representing a 9.1% YoY (year-over-year) fall in operating revenues, including revenues from emerging markets.

Excluding revenues from emerging markets, the franchise reported revenues of 1.30 billion euros for 3Q17—a 14.8% YoY decline.

Cardiovascular products

SNY’s cardiovascular products include Multaq and Praluent. The combined revenues for these drugs was 123 million euros in 3Q17, or 4% higher YoY, including revenues from emerging markets.

If we exclude revenues from emerging markets, Multaq sales fell 4.6% to 80 million euros in 3Q17, while Praluent sales rose 26.5% to 41 million euros.

Diabetes products

SNY’s diabetes products include Lantus and Toujeo. Diabetes products reported revenues of 1.55 billion euros in 3Q17, or 10% lower YoY, including revenues from emerging markets. If we exclude emerging markets sales, diabetes products reported revenues of 1.18 billion euros for 3Q17—a 16.3% YoY fall.

Lantus reported revenues of 867 million euros for 3Q17, which was 22% lower YoY, excluding emerging market sales. This fall was driven by lower sales from the US and in European markets.

Toujeo reported revenues of 179 million euros in 3Q17—14% higher YoY—excluding emerging market sales. This growth was driven by strong sales from all major markets outside the US.

Notably, the VanEck Vectors Pharmaceuticals ETF (PPH) has 4.8% of its total investments in Sanofi ADR (SNY), 4.3% in Eli Lilly (LLY), 4.7% in Mylan NV (MYL), and 4.9% in Merck (MRK).

More From Market Realist